---
input_text: 'Treosulfan-based conditioning regimen in pediatric hematopoietic stem
  cell transplantation: A retrospective analysis on behalf of the Spanish Group for
  Hematopoietic Transplantation and Cellular Therapy (GETH-TC). INTRODUCTION: Data
  on treosulfan-based conditioning regimens are little by little increasing, and the
  benefits of this approach are consistent, particularly regarding acute toxicity.
  This study aims to describe the results of treosulfan-based conditioning regimens
  in children, focusing on toxicity and outcomes when used to treat both malignant
  and non-malignant diseases. METHODS: Retrospective observational study on pediatric
  patients treated in Spain with treosulfan-based conditioning regimens before hematopoietic
  stem cell transplantation (HSCT), based on data collection from electronic clinical
  records. RESULTS: One hundred and sixty treosulfan-based conditioning HSCTs to treat
  non-malignant diseases (n=117) or malignant diseases (n=43) in 158 children and
  adolescents are reported. Median age at HSCT was 5.1 years (IQR: 2-10). The most
  frequent diagnoses were primary immunodeficiency (n=42; 36%) and sickle cell disease
  (n=42; 36%) in the non-malignant cohort and acute lymphoblastic leukemia (n=15;
  35%) in the malignant cohort. Engraftment occurred in 97% of the patients. There
  was a longer median time to neutrophil engraftment (17 vs. 14 days; p=0.008) and
  platelet engraftment (20 vs. 15 days; p=0.002) in the non-malignant cohort. The
  1-year cumulative incidence of VOD was 7.98 (95%CI [4.6-13.6]), with no significant
  differences between cohorts. The 1-year cumulative incidence of grade III-IV aGvHD
  was higher in the malignant cohort (18% vs. 3.2%; p=0.011). Overall, cGvHD was more
  frequently observed in the malignant cohort for both total incidence (9 vs. 3%;
  p<0.001) and 2-year cumulative incidence of total cGvHD (16 vs. 1.9%; p<0.001).
  The 2-year cumulative TRM was 15%, with no differences between cohorts. 5-year Overall
  Survival was 80% (95%CI [72-86]) and was higher in the non-malignant cohort (87
  vs. 61%; p=0.01). The 2-year cumulative incidence of relapse in the malignant cohort
  was 25%. 5-year cumulative GRFS rate was 60% (95%CI [51-70]) and was higher in the
  non-malignant cohort (72 vs. 22%; p<0.001). CONCLUSIONS: The treosulfan-based radiation-free
  conditioning regimen is feasible, achieving a high engraftment rate and 5-year overall
  survival. A treosulfan-based conditioning regimen is an emerging option for the
  first HSCT in non-malignant diseases.'
raw_completion_output: |-
  primary_disease: Hematopoietic stem cell transplantation (HSCT) conditioning
  medical_actions: Treosulfan-based conditioning regimen; Hematopoietic stem cell transplantation
  symptoms: Acute toxicity; Delayed neutrophil engraftment; Delayed platelet engraftment; Venous occlusive disease (VOD); Grade III-IV acute graft-versus-host disease (aGvHD); Chronic graft-versus-host disease (cGvHD); Transplantation-related mortality (TRM); Relapse
  chemicals: Treosulfan
  action_annotation_relationships: Treosulfan-based conditioning regimen TREATS acute toxicity IN HSCT conditioning; Treosulfan-based conditioning regimen PREVENTS delayed neutrophil engraftment IN HSCT conditioning; Treosulfan-based conditioning regimen PREVENTS delayed platelet engraftment IN HSCT conditioning; Treosulfan-based conditioning regimen PREVENTS venous occlusive disease (VOD) IN HSCT conditioning; Treosulfan-based conditioning regimen TREATS grade III-IV acute graft-versus-host disease (aGvHD) IN HSCT conditioning; Treosulfan-based conditioning regimen TREATS chronic graft-versus-host disease (cGvHD) IN HSCT conditioning; Treosulfan-based conditioning regimen PREVENTS transplantation-related mortality (TRM) IN HSCT conditioning; Treosulfan-based conditioning regimen PREVENTS relapse IN HSCT conditioning
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Treosulfan-based conditioning regimen PREVENTS relapse IN HSCT conditioning

  ===

extracted_object:
  primary_disease: Hematopoietic stem cell transplantation (HSCT) conditioning
  medical_actions:
    - Treosulfan-based conditioning regimen
    - MAXO:0000747
  symptoms:
    - Acute toxicity
    - Delayed neutrophil engraftment
    - Delayed platelet engraftment
    - HP:0025322
    - Grade III-IV acute graft-versus-host disease (aGvHD)
    - Chronic graft-versus-host disease (cGvHD)
    - Transplantation-related mortality (TRM)
    - Relapse
  chemicals:
    - CHEBI:82557
  action_annotation_relationships:
    - subject: MAXO:0000750
      predicate: TREATS
      object: acute toxicity
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: PREVENTS
      object: delayed neutrophil engraftment
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: PREVENTS
      object: delayed platelet engraftment
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: PREVENTS
      object: HP:0025322
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: TREATS
      object: acute graft-versus-host disease
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      object_qualifier: grade III-IV
      subject_extension: CHEBI:82557
      object_extension: grade III-IV
    - subject: MAXO:0000750
      predicate: TREATS
      object: chronic graft-versus-host disease
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: PREVENTS
      object: transplantation-related mortality
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
    - subject: MAXO:0000750
      predicate: PREVENTS
      object: relapse
      qualifier: HSCT conditioning
      subject_qualifier: Treosulfan-based
      subject_extension: CHEBI:82557
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
